5 questions answered from cited research · Plain language
Yes, the Systemic Immune-Inflammation Index (SII) can help predict lymph node metastasis in thyroid cancer, with studies showing moderate diagnostic accuracy.
Read the full answer →Yes, immune microenvironment characterization helps identify immune subtypes and biomarkers to guide precision immunotherapy in thyroid cancer, especially for aggressive forms.
Read the full answer →Yes, encorafenib plus binimetinib is effective for BRAF V600E-mutated thyroid cancer, with a 54.5% objective response rate in a phase 2 trial, including responses in both differentiated and anaplastic subtypes.
Read the full answer →Yes, the gut microbiome likely influences thyroid cancer development through immune regulation, hormone metabolism, and metabolite production, though direct evidence in humans is still limited.
Read the full answer →Yes, the Systemic Immune-Inflammation Index (SII) shows moderate diagnostic accuracy for thyroid cancer, with pooled sensitivity of 76.8% and specificity of 71.2% based on a meta-analysis.
Read the full answer →